This sleep treatment company’s shares could be in the buy zone…
The post Top broker says ResMed (ASX:RMD) share price is a buy appeared first on The Motley Fool Australia. –
The ResMed Inc. (ASX: RMD) share price has been a very strong performer in 2021.
Since the start of the year, the sleep treatment focused medical device company’s shares have gained 35% to $37.12.
This leaves the ResMed share price trading within sight of its record high of $40.79.
Can the ResMed share price keep rising?
The good news is that it may not be too late to buy ResMed shares.
According to a recent note out of Credit Suisse, its analysts have retained their outperform rating and lifted their price target on the company’s shares to $44.00.
Based on the current ResMed share price, this implies potential upside of 18.5% over the next 12 months.
What did the broker say?
Credit Suisse was pleased with the company’s investor day event this month.
It notes that ResMed is expecting to benefit from upwards of US$350 million in incremental sales in FY 2022 from the Philips product recall. The broker also suspects that sustained market share gains will be achieved because of the recall and feels the market is underestimating this.
Particularly given how management advised that it has seen a measurable elevation in mask sales arising from this issue.
In addition, ResMed has revealed plans to expand its patient reach with a new partnership with US pharmacy giant CVS Health. Credit Suisse suspects that these new channels will help sustain device growth rates above the industry average over the long term. This is because the CVS pharmacy network provides broad penetration across the community channel. Approximately 75% of the US population live within 5 miles of a CVS store.
All in all, it feels this makes the ResMed share price good value at the current level.
Should you invest $1,000 in ResMed right now?
Before you consider ResMed, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.